AAPL 228.6 0.4261% MSFT 412.7838 0.7404% NVDA 134.1695 3.3345% GOOGL 186.805 0.7904% GOOG 188.574 0.7663% AMZN 232.82 1.6016% META 715.35 0.1162% AVGO 235.392 4.6791% LLY 864.92 -1.5245% TSLA 358.0225 -0.9948% TSM 207.7 0.7665% V 351.34 0.954% JPM 271.4399 -1.5809% UNH 527.98 0.1803% NVO 83.95 -2.8581% WMT 102.26 1.0974% LVMUY 141.59 0.6826% XOM 110.81 1.7632% LVMHF 707.0 0.6105% MA 566.5 0.6664%
Last update at 2025-02-07T14:30:00Z
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
Fri 07 Feb 25, 06:04 PMBMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?
Mon 27 Jan 25, 04:40 PMIs CSL Limited (ASX:CSL) Trading At A 30% Discount?
Fri 10 Jan 25, 10:23 PMCSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
Fri 13 Dec 24, 03:38 PMCSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform
Mon 09 Dec 24, 01:00 PMGSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
Fri 04 Oct 24, 04:31 PMBreakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Income before tax | 2663.00M | 2779.60M | 2963.10M | 2572.70M | 2341.10M |
Minority interest | -50.00000M | - | - | - | 0.00000M |
Net income | 2194.00M | 2254.70M | 2375.00M | 2102.50M | 1918.70M |
Selling general administrative | 1086.00M | 688.00M | 731.70M | 691.80M | 574.80M |
Selling and marketing expenses | 1454.00M | 960.70M | 980.20M | 896.20M | 866.80M |
Gross profit | 6708.00M | 5663.50M | 5798.60M | 5176.10M | 4748.70M |
Reconciled depreciation | 831.00M | 542.50M | 495.30M | 610.96M | 536.03M |
Ebit | 3071.00M | 2922.40M | 3130.00M | 2723.50M | 2517.80M |
Ebitda | 3902.00M | 3464.90M | 3629.20M | 3143.30M | 2893.20M |
Depreciation and amortization | 831.00M | 542.50M | - | 419.80M | 375.40M |
Non operating income net other | - | - | - | - | 0.00000M |
Operating income | 3071.00M | 2922.40M | 3629.20M | 2723.50M | 2517.80M |
Other operating expenses | 11072.00M | 8177.00M | 7675.30M | 6854.10M | 6410.00M |
Interest expense | 408.00M | 142.80M | 170.80M | 150.80M | 176.70M |
Tax provision | 419.00M | 524.90M | 588.10M | 685.12M | 602.31M |
Interest income | 38.00M | 17.40M | 3.90M | 10.20M | 19.68M |
Net interest income | -406.00000M | -160.60000M | -166.90000M | -209.52936M | -232.28290M |
Extraordinary items | - | - | - | - | 0.00000M |
Non recurring | - | - | - | - | 0.00000M |
Other items | - | - | - | - | 0.00000M |
Income tax expense | 419.00M | 524.90M | 588.10M | 470.20M | 422.40M |
Total revenue | 13174.00M | 10493.10M | 10265.30M | 9100.50M | 8509.90M |
Total operating expenses | 4606.00M | 3347.40M | 3208.60M | 2929.70M | 2648.80M |
Cost of revenue | 6466.00M | 4829.60M | 4466.70M | 3924.40M | 3761.20M |
Total other income expense net | 136.00M | 81.60M | 44.70M | 50.30M | 28.70M |
Discontinued operations | - | - | - | - | 0.00000M |
Net income from continuing ops | 2244.00M | 2254.70M | 2375.00M | 3063.53M | 2735.92M |
Net income applicable to common shares | 2194.00M | 2254.70M | 2375.00M | 2102.50M | 1918.70M |
Preferred stock and other adjustments | - | - | - | - | 0.00000M |
Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
Total assets | 38022.00M | 36234.00M | 28346.00M | 18156.90M | 15464.60M |
Intangible assets | 8267.00M | 8367.00M | 1450.80M | 1481.60M | 986.00M |
Earning assets | - | - | - | - | - |
Other current assets | 506.00M | 9.00M | 4.20M | 236.60M | 184.10M |
Total liab | 18621.00M | 18408.00M | 13768.50M | 9775.60M | 8937.20M |
Total stockholder equity | 17363.00M | 15786.00M | 14577.50M | 8381.30M | 6527.40M |